How a pharma company experiences ordering, manufacturing and delivering a personalized cell therapy to a cancer patient: stage by stage, with the friction, the decision and the value at each handoff.
Cells are taken from a patient, shipped to a manufacturing facility, engineered into medicine and returned for infusion. The entire chain is FDA-regulated, time-sensitive and patient-specific. Every product is made for one person. If identity is lost at any point, the therapy cannot be used.
The friction is not concentrated in one place. It repeats at every handoff, which is why no single participant could fix it. Scroll the table sideways →
Physician prescribes the therapy. The coordinating nurse calls in the order. Patient demographics, prescriber information and scheduling details are captured.
Patient arrives at a certified apheresis center. A nurse draws blood and separates white blood cells. The kit is labeled with patient-specific identifiers.
A courier collects the kit for temperature-controlled shipping to the manufacturing facility. Chain of custody transfers at each handoff.
The facility confirms identity and begins engineering. Cells are modified, expanded, tested for quality and packaged as finished product.
The finished product is packaged in a cryogenic shipper and transported back to the treatment site, temperature and location tracked throughout.
The hospital confirms the patient identity match. The patient undergoes conditioning, infusion is administered, and outcome monitoring begins.
Prescribing physician, coordinating nurse, hospital call center, pharma commercial team.
Apheresis nurse, patient, hospital scheduling, pharma commercial team.
Courier service, pharma logistics, receiving dock at the manufacturing site.
Manufacturing team, quality assurance, pharma regulatory, batch release reviewers.
Courier service, pharma logistics, hospital receiving.
Treating physician, infusion nurse, patient, pharmacy, pharma medical affairs.
Cautious optimism. First interaction with a new vendor. Will this work for our workflow?
High anxiety. The patient is physically present. Any error means starting over.
A blind spot. No direct visibility once it is in transit. Where is it right now?
Waiting. The longest phase. The customer checks in periodically. Is it on schedule?
Anticipation. The patient has been prepped. If shipping fails, the conditioning window may close.
Relief and focus. The product arrived, identity confirmed. Now it is clinical execution.
Orders placed by phone and typed into spreadsheets. Transcription errors in patient names and addresses were common.
If the center is not certified for this specific therapy the collection cannot happen, and certification status was not tracked centrally.
Multiple courier handoffs on paper chain-of-custody forms. A lost or mislabeled form means rejection at receiving.
Batch failures happen. A failed release restarts the process from collection, and no system coordinated the re-order.
Conditioning is timed to arrival. A delay of even twenty-four hours can push the patient outside their treatment window.
Final identity verification was manual, and a mismatch — the wrong patient receiving the wrong cells — is catastrophic and irreversible.
Does pharma mandate the platform for all sites, or allow sites to continue on phone and fax?
Does the platform verify site certification automatically, or does the coordinator check manually before scheduling?
Does the sponsor want real-time courier tracking integrated, or is email notification sufficient?
When a batch fails, who initiates the re-order: the manufacturing site, the pharma team, or the platform automatically?
How much lead time does the hospital need before the product ships? Too little and they cannot prep; too much and they hold a bed.
Does the platform generate the final verification checklist, or does the hospital use its own?
Digital order entry with validation rules. Identity verified at the point of entry. Scheduling conflicts flagged before they became problems.
Kit labeling generated from the order record, not hand-written. Scan-based verification confirms the right kit matched to the right patient.
Digital chain of custody. Every handoff scanned and timestamped, with real-time alerts on temperature excursion or delay.
Manufacturing status visible to the sponsor without phone calls, with automated notification at key milestones.
Scheduling coordinated between manufacturing completion and hospital readiness, with both sides alerted when timing was at risk.
Final verification built into the workflow: digital confirmation that the product matches the patient before the infusion team proceeds.
The scarce resources in this chain are apheresis slots, manufacturing runs, cryogenic transport windows and conditioned patients. Every lost form, uncertified site or failed identity check consumes them twice — and no single participant controlled the whole journey, so no one was accountable for the rework.
Identity fidelity, digital custody and shared visibility were the mechanisms. The leverage was fewer restarts, fewer missed treatment windows and constrained capacity used once.
That is the same reading applied to any operating-leverage question: name the constrained resource, find the handoff where the economics break, and intervene no further than that.
Each stage is one step in the therapy journey from the customer’s perspective — the pharma company’s. The rows show what is happening, who is involved, the customer’s state, where friction occurs, where a decision has to be made, and where the platform delivered value.
Built from operating experience at an early-stage cell and gene therapy orchestration platform. Company and customer names anonymized.